- Conditions
- Prostate Cancer, High-risk Prostate Cancer
- Interventions
- Darolutamide, Pembrolizumab, Lupron
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 21, 2026, 7:12 PM EDT